Company Website: http://www.zlk.com
NEW YORK -- (Business Wire)

Levi & Korsinsky, LLP is investigating Alcobra Ltd. (“Alcobra” or the “Company”) (NasdaqGM: ADHD) in connection with possible violations of federal securities laws by the Board of Directors of the Company.

To get more information, click here: http://zlk.9nl.com/alcobra-adhd. There is no cost or obligation to you.

On October 6, 2014, the Company announced topline results from its Phase III study of experimental drug MDX for the treatment of Adult ADHD, declaring that the drug demonstrated a statistically significant improvement in ADHD symptoms. Then on October 22, 2014, the Company announced that the study did not, in fact, demonstrate said improvement.

If you own common stock in Alcobra and wish to obtain additional information, please contact Eduard Korsinsky, Esq. either via email at ek@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/alcobra-adhd.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s 26 attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts:

Levi & Korsinsky, LLP
Eduard Korsinsky, Esq., 212-363-7500
Toll Free: 877-363-5972
Fax: 866-367-6510
www.zlk.com

Source: Levi & Korsinsky, LLP